Brief communication
The management of desmoid tumors

https://doi.org/10.1016/0360-3016(93)90501-LGet rights and content

Abstract

Purpose: To determine the efficacy of different treatment modalities for desmoid tumors.

Materials and Methods: We reviewed the treatment of 40 patients with histologically confirmed desmoid tumors seen at Duke University Medical Center between 1974 and 1990.

Results: Radiotherapy was administered to 16 patients (Group I)—14 with recurrent disease s/p surgery and in two as initial treatment. The average size of the irradiated lesions was 9.3 ± 3.9 × 8.4 ± 3.5 cm. With a median follow-up of 57.5 months and a median administered dose of 5400 cGy (mean 5286 cGy, range 4960–5620 cGy), local control has been obtained in 1516 patients (94%). Complete regression (516), partial regression (516), or stable disease (516) was produced in 15 patients while one patient failed and was salvaged via gross total resection. Continued regression has been seen up to 60 months after treatment. Fourteen patients underwent primary gross total resection and two underwent subtotal resection (Group II). None received post-operative radiotherapy. Three of 14 patients (21%) recurred after gross total resection. All three were salvaged with subsequent gross total resection. After subtotal resection, 22 patients recurred. With a mean follow-up of 52 months, 14 patients are without evidence of disease, one is dead with disease (unrelated cause of death), and one was lost to follow-up after recurrence. Eight patients have been treated with combinations of chemotherapy, NSAIDS, anti-estrogens, and immunotherapy with mixed results (Group III). A subset of seven patients with retroperitoneal disease taken from all three groups had large tumor burden (mean size 17 × 15 cm), an infiltrative nature, as well as a difficult location. The disease was surgically resectable in three patients. One is without evidence of disease 9 years after gross total resection alone. Disease has been stabilized with radiotherapy in the other two patients after multiple unsuccessful surgical resections. Of four patients with unresectable disease, two are dead of disease, one died of unrelated causes with disease, and regression of disease was obtained in the other with Gamma-interferon after unsuccessful treatment with tamoxifen and vincristine, doxorubicin, and cyclophosphamide chemotherapy.

Conclusion: Gross total resection is the indicated initial therapy, if it can be performed without significant disfigurement. Radiotherapy is also excellent for obtaining local control, even in patients with a large burden of recurrent disease. Doses in the range of 50 to 55 Gy give a chance of local control equal to that obtained with higher doses previously reported.

References (38)

  • L.J. Taylor

    Musculoaponeurotic fibromatosis, a report of 28 cases and review of the literature

    Clin. Orthol Rel. Research

    (1987)
  • T.K. Das Gupta et al.

    Extra-abdominal desmoids: A clinicopathologic study

    Annals of Surgery

    (1969)
  • F.M. Enzinger et al.

    Musculo-aponeurotic fibromatosis of the shoulder girdle (extra-abdominal desmoid). Analysis of thirty cases followed up for ten or more years

    Cancer

    (1967)
  • F.M. Enzinger et al.

    Soft tissue tumors

  • J. Ewing

    Neoplastic Diseases

    (1928)
  • E.C. Halperin et al.

    Pediatric Radiation Oncology

    E.C. Halperin et al.

    Pediatric Radiation Oncology

  • N.H. Jenkins et al.

    Spontaneous regression of a desmoid tumor

    J. Bone Joint Surg.

    (1986)
  • E.L. Kaplan et al.

    Nonparametric estimation from incomplete observation

    J. Am. Stat. Assoc.

    (1958)
  • R. Keus et al.

    The role of radiotherapy in the treatment of desmoid tumors

    Radiother. Oncol.

    (1986)
  • Cited by (110)

    • Soft Tissue Tumors of the Abdomen and Retroperitoneum

      2020, Surgical Clinics of North America
      Citation Excerpt :

      In the postoperative setting, radiation therapy is not recommended, given that there is no conclusive advantage.91,92 Patients with disease unamenable to surgery may benefit from consultation with a sarcoma medical oncologist or radiation oncologist.93 To determine the applicability and safety of an initial observation strategy, the initiation of medical therapy, or the consideration for resection, the international collaborative of the Desmoid Tumor Working Group recommends coordinated management with a multidisciplinary team of sarcoma clinicians at the time of diagnosis.79,90,94

    • The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients

      2020, European Journal of Cancer
      Citation Excerpt :

      This modality can be a valid alternative to surgery and can be used if medical therapies are not available or not active. Summarising the data comparing radiotherapy to surgery [33]; “very low” according to GRADE, the anticipated absolute risk of progressive disease after radiotherapy alone is 19% versus 29% after surgery alone, however, not being statistically significant (RR 0.65, 95% CI 0.35–1.22). In summary, when active management for DT is required, surgery as first-line therapy can be considered, provided expected surgical morbidity is limited.

    • Bone Sarcomas and Desmoids

      2020, Hematology/Oncology Clinics of North America
    • Conservative management of desmoid tumors is safe and effective

      2016, Journal of Surgical Research
      Citation Excerpt :

      Although desmoid tumors do not metastasize, they can be locally infiltrative causing symptoms, such as pain and neuropathy, and in their most severe forms may be limb threatening.2 Historically, the standard treatment approach for desmoid tumors was surgical resection.1,3,4 However, because of the infiltrative nature of these tumors, many series have reported high rates of local recurrence after surgical resection, ranging from 20% to 50%.5-7

    • Musculoskeletal Disorders

      2023, Medical Radiology
    View all citing articles on Scopus

    Presented at the 34th Annual Meetings of the American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting, San Diego, CA, 8–13 November 1992.

    Dept. of Radiation Oncology.

    Dept. of Pathology.

    View full text